Author
Montserrat Forné
Other affiliations: Carlos III Health Institute
Bio: Montserrat Forné is an academic researcher from University of Barcelona. The author has contributed to research in topics: Microscopic colitis & Lymphocytic colitis. The author has an hindex of 29, co-authored 64 publications receiving 4106 citations. Previous affiliations of Montserrat Forné include Carlos III Health Institute.
Papers published on a yearly basis
Papers
More filters
TL;DR: Results indicate that long‐term selective intestinal decontamination with norfloxacin is an effective and safe measure to prevent spontaneous bacterial peritonitis recurrence caused by aerobic gram‐negative bacilli in cirrhosis.
574 citations
TL;DR: Patients with Crohn’s disease who are candidates for infliximab therapy should be tested for hepatitis B serological markers before treatment and considered for prophylaxis of reactivation using antiviral therapy if positive.
Abstract: Background: There is little information about the effect of infliximab on the clinical course of liver disease in Crohn’s disease patients with concomitant hepatitis B virus (HBV) infection. Theoretically, immunosuppression induced by infliximab will facilitate viral replication which could be followed by a flare or exacerbation of disease when therapy is discontinued. There are no specific recommendations on surveillance and treatment of HBV before infliximab infusion. Two cases of severe hepatic failure related to infliximab infusions have been described in patients with rheumatic diseases.
Patients and methods: Hepatitis markers (C and B) and liver function tests were prospectively determined to 80 Crohn’s disease patients requiring infliximab infusion in three hospitals in Spain.
Results: Three Crohn’s disease patients with chronic HBV infection were identified. Two of the three patients with chronic HBV infection suffered severe reactivation of chronic hepatitis B after withdrawal of infliximab therapy and one died. A third patient, who was treated with lamivudine at the time of infliximab therapy, had no clinical or biochemical worsening of liver disease during or after therapy. From the remaining 80 patients, six received the hepatitis B vaccine. Three patients had antibodies to both hepatitis B surface antigen (anti-HBs) and hepatitis B core protein (anti-HBc) with normal aminotransferase levels, and one patient had positive anti-hepatitis C virus (HCV) antibodies, negative HCV RNA, and normal aminotransferase levels. Except for the patients with chronic HBV infection, no significant changes in hepatic function were detected.
Conclusions: Patients with Crohn’s disease who are candidates for infliximab therapy should be tested for hepatitis B serological markers before treatment and considered for prophylaxis of reactivation using antiviral therapy if positive.
459 citations
TL;DR: Antisecretory agent or nitrate treatment is associated with reduced UGIB RR in patients taking NSAID or aspirin, and protection was not apparent in patientsTaking anticoagulants.
298 citations
TL;DR: The incidence of lymphocytic colitis is three times higher than that of collagenous colitis and should be considered as a major possibility in the work-up of chronic diarrhea in older women.
271 citations
TL;DR: Nonazotemic cirrhotic patients with uncomplicated community-acquired spontaneous bacterial peritonitis and without hepatic encephalopathy have an excellent prognosis and may be treated with oral ofloxacin without requiring hospitalization, as well as intravenous cefotaxime in this infection.
228 citations
Cited by
More filters
TL;DR: The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B is now posted online at www.aasld.org, and the recommendation for first-line oral antiviral medications has been changed to tenofovir or entecavir, and adefovir has been moved to second-line Oral antiviral medication.
2,696 citations
Otto-von-Guericke University Magdeburg1, University of Bordeaux2, Trinity College, Dublin3, Erasmus University Medical Center4, University of Bologna5, University of Nottingham6, Veterans Health Administration7, McMaster University8, University of Padua9, Hochschule Hannover10, University of New South Wales11
TL;DR: This fifth edition of the Maastricht Consensus Report describes how experts from 24 countries examined new data related to H. pylori infection in the various clinical scenarios and provided recommendations on the basis of the best available evidence and relevance.
Abstract: Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role of H. pylori were re-evaluated in 2015. In the Maastricht V/Florence Consensus Conference, 43 experts from 24 countries examined new data related to H. pylori in five subdivided workshops: (1) Indications/Associations, (2) Diagnosis, (3) Treatment, (4) Prevention/Public Health, (5) H. pylori and the Gastric Microbiota. The results of the individual workshops were presented to a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in the various clinical scenarios.
2,219 citations
TL;DR: The panel of experts, having emphasised the importance of initiating aetiologic treatment for any degree of hepatic disease at the earliest possible stage, extended its work to all the complications of cirrhosis which had not been covered by the European Association for the Study of the Liver guidelines.
1,534 citations
1,530 citations
TL;DR: There is a clear rationale for the management of ascites in patients with cirrhosis, as successful treatment may improve outcome and symptoms, and patients with ascites should generally be considered for referral for liver transplantation.
1,476 citations